lamivudine/zidovudine/efavirenz / Viatris, Strides Pharma Science - LARVOL DELTA

Outcomes of HIV-infected children on antiretroviral therapy for at least 10 years at the Essos Hospital Centre, Cameroon: contributing to the elimination of paediatric AIDS in tropical settings. (PubMed, J Trop Pediatr) - "At ART initiation among the 90 eligible children, median (interquartile range) age was 29.5 (11-60) months, 53.3% were males, 34.5% were at WHO clinical stage 1/2, median-CD4 was 497 cells/mm3, and initial ART-regimens were mainly zidovudine-lamivudine-nevirapine (85.5%) and zidovudine-lamivudine-efavirenz (12.2%)...In this LMIC, long-term outcomes of children on ART appear encouraging, characterized by moderate VS rate and immune recovery. However, challenges in achieving viral undetectability indicate continuous viral replication and risks of drug resistance emergence that may jeopardize effectiveness of future paediatric ART strategies."

Journal • Observational data • Retrospective data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • CD4

Virologic Response Following a Switch to Dolutegravir-based Regimen in People Living with HIV/AIDS at a Tertiary Care Center in Nepal. (PubMed, Kathmandu Univ Med J (KUMJ)) - "Method This is a retrospective cohort study including people living with human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS) who were transitioned to Tenofovir/Lamivudine/Dolutegravir previously on other antiretroviral therapy regimens for at least 6 months and who had their viral load test done before transition...Tenofovir/Lamivudine/Efavirenz (47.4%), Zidovudine/ Lamivudine/Nevirapine (22.8%) and Zidovudine/Lamivudine/Efavirenz (17.5%) were the most common antiretroviral regimens before transition...Following the transition, 96.5% of the patients had suppressed viral load of fewer than 40 copies/mL. Conclusion Dolutegravir-based antiretroviral regimen led to untransmittable viral load following a switch from Nevirapine and Efavirenz-based regimen."

Journal • Human Immunodeficiency Virus • Infectious Disease

Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana. (PubMed, AIDS Res Ther) - "Approximately 76% viral suppression rate among HIV patients on ART in Kumasi falls below the WHO 95% target by the year 2030. Choice of ART combination, drug adherence, WHO clinical staging and baseline viral load are factors associated with suppression or rebound. These clinical characteristics of HIV patients must be monitored concurrently with the viral load."

Journal • Retrospective data • Review • Human Immunodeficiency Virus • Immunology • Infectious Disease

Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen. (PubMed, Chin Med J (Engl)) - "The incidence of dyslipidemia varies with different antiretroviral regimens, with TDF + 3TC + EFV having lower risk for dyslipidemia than the other first-line free antiretroviral regimens in China."

Clinical • Journal • Cardiovascular • Dyslipidemia • Genetic Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Metabolic Disorders • Obesity

VADICT: Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids (clinicaltrials.gov) - P=N/A; N=194; Completed; Sponsor: Obafemi Awolowo University; Active, not recruiting ➔ Completed; Trial completion date: Dec 2020 ➔ Sep 2020; Trial primary completion date: Nov 2020 ➔ Dec 2019

Clinical • Trial completion • Trial completion date • Trial primary completion date • Human Immunodeficiency Virus • Immunology • Infectious Disease

Effectiveness of four antiretroviral regimens for treating people living with HIV. (PubMed, PLoS One) - "Some differences may be due to the individual characteristics of patients, toxicity and acceptability of drugs. Studies are needed that compare similarly effective regimens and their respective treatment costs and financial impacts on SUS (Integrated Healthcare System)."

Journal • Human Immunodeficiency Virus • Infectious Disease